Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.195 EUR | -0.76% | -6.06% | -21.76% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
Sales 2023 * | 15.31M 16.29M | Sales 2024 * | 19.79M 21.06M | Capitalization | 245M 260M |
---|---|---|---|---|---|
Net income 2023 * | -42M -44.7M | Net income 2024 * | -42M -44.7M | EV / Sales 2023 * | 17.6 x |
Net Debt 2023 * | 24.2M 25.76M | Net Debt 2024 * | 24.35M 25.92M | EV / Sales 2024 * | 13.6 x |
P/E ratio 2023 * |
-6.07
x | P/E ratio 2024 * |
-6.52
x | Employees | 101 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.58% |
Latest transcript on Nanobiotix
1 day | -0.76% | ||
1 week | -7.89% | ||
Current month | -8.86% | ||
1 month | -6.40% | ||
3 months | -27.85% | ||
6 months | -16.61% | ||
Current year | -21.76% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Lévy
CEO | Chief Executive Officer | 53 | 03-03-03 |
Bart van Rhijn
DFI | Director of Finance/CFO | 52 | 21-05-31 |
Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CHM | Chairman | 58 | 21-05-24 |
Enno Spillner
BRD | Director/Board Member | 55 | 14-06-17 |
Alain Herrera
BRD | Director/Board Member | 74 | 11-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 5.195 | -0.76% | 35,872 |
24-04-17 | 5.235 | -3.06% | 56,248 |
24-04-16 | 5.4 | +1.03% | 58,521 |
24-04-15 | 5.345 | +2.00% | 36,779 |
24-04-12 | 5.24 | -5.24% | 67,348 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.76% | 262M | |
-1.82% | 41.36B | |
+44.25% | 41.3B | |
+2.56% | 39.61B | |
-12.11% | 25.62B | |
+3.09% | 24.09B | |
-24.16% | 18.38B | |
+22.12% | 11.85B | |
-3.74% | 11.82B | |
+7.75% | 11.07B |
- Stock Market
- Equities
- NANO Stock